Clinical Trials
16 trialsNCT03554707 2026-05-08
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT00876993 2023-07-03
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Johns Hopkins All Children's Hospital
Phase 1 Completed
NCT01217437 2021-07-23
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT01201850 2021-05-19
The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
University of Colorado, Denver
Phase NA Terminated
NCT01013285 2020-09-21
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00337207 2020-02-07
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
Northwestern University
Phase 2 Completed
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01164189 2019-02-28
TAVAREC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed
NCT00621686 2018-05-08
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01052363 2017-02-09
OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas
West Virginia University
Phase 1 Withdrawn
NCT00756340 2015-10-14
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00352521 2014-07-22
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Duke University
Phase 2 Completed
NCT00268359 2014-07-21
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Duke University
Phase 2 Completed
NCT00501891 2013-05-27
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
Duke University
Phase 2 Completed